Atossa Therapeutics, Inc.

DB:YAG2 Stock Report

Market Cap: €146.2m

Atossa Therapeutics Balance Sheet Health

Financial Health criteria checks 6/6

Atossa Therapeutics has a total shareholder equity of $73.7M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $79.5M and $5.8M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$74.77m
EquityUS$73.68m
Total liabilitiesUS$5.80m
Total assetsUS$79.48m

Recent financial health updates

Recent updates

Financial Position Analysis

Short Term Liabilities: YAG2's short term assets ($77.1M) exceed its short term liabilities ($5.8M).

Long Term Liabilities: YAG2 has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: YAG2 is debt free.

Reducing Debt: YAG2 has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: YAG2 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: YAG2 has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 16.6% each year


Discover healthy companies